Cognition Therapeutics, Inc. Interest Income (Expense), Net
Cognition Therapeutics, Inc. (CGTX) reported Interest Income (Expense), Net of -$10.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2024-05-07
- Cognition Therapeutics, Inc. interest income (expense), net for the quarter ending 2024-03-31 was -$10.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for the quarter ending 2023-12-31 was -$9.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for the quarter ending 2023-09-30 was -$2.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for the quarter ending 2023-06-30 was -$6.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for fiscal 2023 was -$27.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for fiscal 2022 was -$28.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for fiscal 2021 was -$893.00K.
- Cognition Therapeutics, Inc. interest income (expense), net for fiscal 2020 was -$1.75M.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$10.00K 10-Q · filed 2024-05-07 | -$19.00K derived: sum of 2 quarters · filed 2024-05-07 | -$21.00K derived: sum of 3 quarters · filed 2024-05-07 | -$27.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$11.00K derived: sum of 2 quarters · filed 2024-03-26 | -$17.00K derived: sum of 3 quarters · filed 2024-03-26 | -$27.00K 10-K · filed 2024-03-26 |
| 2023-09-30 | -$2.00K 10-Q · filed 2023-11-02 | -$8.00K derived: sum of 2 quarters · filed 2023-11-02 | -$18.00K 10-Q · filed 2023-11-02 | -$28.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | -$6.00K 10-Q · filed 2023-08-08 | -$16.00K 10-Q · filed 2023-08-08 | -$26.00K derived: sum of 3 quarters · filed 2024-05-07 | -$28.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | -$10.00K 10-Q · filed 2024-05-07 | -$20.00K derived: sum of 2 quarters · filed 2024-05-07 | -$22.00K derived: sum of 3 quarters · filed 2024-05-07 | -$29.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$12.00K derived: sum of 2 quarters · filed 2024-03-26 | -$19.00K derived: sum of 3 quarters · filed 2024-03-26 | -$28.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$2.00K 10-Q · filed 2023-11-02 | -$9.00K derived: sum of 2 quarters · filed 2023-11-02 | -$18.00K 10-Q · filed 2023-11-02 | -$17.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$7.00K 10-Q · filed 2023-08-08 | -$16.00K 10-Q · filed 2023-08-08 | -$15.00K derived: sum of 3 quarters · filed 2023-08-08 | -$15.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$9.00K 10-Q · filed 2023-05-04 | -$8.00K derived: sum of 2 quarters · filed 2023-05-04 | -$8.00K derived: sum of 3 quarters · filed 2023-05-04 | -$365.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.00K derived: sum of 2 quarters · filed 2023-03-23 | -$356.00K derived: sum of 3 quarters · filed 2023-03-23 | -$893.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$357.00K derived: sum of 2 quarters · filed 2022-11-14 | -$894.00K 10-Q · filed 2022-11-14 | -$1.42M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$357.00K 10-Q · filed 2022-08-09 | -$894.00K 10-Q · filed 2022-08-09 | -$1.42M derived: sum of 3 quarters · filed 2022-08-09 | -$1.93M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$537.00K 10-Q · filed 2022-05-11 | -$1.07M derived: sum of 2 quarters · filed 2022-05-11 | -$1.57M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$1.03M derived: sum of 2 quarters · filed 2022-03-30 | -$1.75M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$506.00K 10-Q · filed 2021-11-17 | -$1.22M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |